Hong Kong unveils next-gen drug for cancers associated with EpsteinâBarr virus
Hong Kong unveils next-gen drug for cancers associated with EpsteinâBarr virus 03 March 2021 | News HKBU has established a spin-off company named BP InnoMed Limited (BPI) to further develop this new anti-EBV drug and carry out clinical trials
Source: PR Newswire
A Hong Kong Baptist University-led (HKBU) research team has developed a novel drug which has the potential to become a next-generation treatment for cancers associated with Epstein–Barr virus (EBV).
The peptide-linked drug, which is responsive to the acidic environment found in tumours, is the first known agent to have successfully targeted two viral proteins that are simultaneously produced by EBV.
Hong Kong Baptist University
A Hong Kong Baptist University-led (HKBU) research team has developed a novel drug which has thepotential to become a
next-generation treatment for cancers associated with Epstein–Barr virus (EBV).
The peptide-linked drug, which is responsive to the acidic environment found in tumours, is the first known agent to have
successfully targeted two viral proteins that are simultaneously produced by EBV. It also offers a new strategy by increasing the uptake of anti-cancer drugs in tumour cells, thus
allowing the application of lower drug dosages which helps reduce treatment side effects and health risks.
The research results were published in the international academic journal
Novel dual-targeting drug could become a next-generation treatment for EBV-related cancers news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
HKBU develops dual-targeting drug for EBV-related cancers finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.